Drugs / [18F] 4-L-Fluoroglutamine (2S,4R)
[18F] 4-L-Fluoroglutamine (2S,4R)
also known as
(18)F-(2S,4R)-4-Fluoroglutamine · 18FFluoroglutamine · F-Glutamine · FGln · fluorine 18-(2S,4R)-4-fluoroglutamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01697930 | Sep 2012 → Sep 2026 overdue | cancer, lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F] 4-L-Fluoroglutamine (2S,4R) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01697930 ↗ |
| Known as | (18)F-(2S,4R)-4-Fluoroglutamine | “In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of (18)F-(2S,4R)-4-Fluoroglutamine.” PMID 29388903 ↗ Jan 2018 |
| Known as | 18FFluoroglutamine | “This study is the first time that a new experimental drug called 18FFluoroglutamine, or F-Glutamine, is being used in people.” NCT01697930 ↗ |
| Known as | F-Glutamine | “This study is the first time that a new experimental drug called 18FFluoroglutamine, or F-Glutamine, is being used in people.” NCT01697930 ↗ |
| Known as | FGln | “Purpose To assess the clinical safety, pharmacokinetics, and tumor imaging characteristics of fluorine 18-(2S,4R)-4-fluoroglutamine (FGln), a glutamine analog radiologic imaging agent.” PMID 29388903 ↗ Jan 2018 |
| Known as | fluorine 18-(2S,4R)-4-fluoroglutamine | “Purpose To assess the clinical safety, pharmacokinetics, and tumor imaging characteristics of fluorine 18-(2S,4R)-4-fluoroglutamine (FGln), a glutamine analog radiologic imaging agent.” PMID 29388903 ↗ Jan 2018 |
| Modality | Diagnostic / imaging agent | “fluorine 18-(2S,4R)-4-fluoroglutamine (FGln), a glutamine analog radiologic imaging agent.” PMID 29388903 ↗ Jan 2018 |
| Route | Intravenous | “The \[18F\] 4-L-Fluoroglutamine (2S,4R) agent will be administered by bolus intravenous injection.” NCT01697930 ↗ |